ASH

AshlandA

NYSE / Materials

At close

2026-07-18

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$77.00

+12.2% vs current

Most likely

Base case

50%

Probability

Target price

$70.00

+2.0% vs current

B-

Bear case

25%

Probability

Target price

$58.00

-15.5% vs current

AI sentiment snapshot

Latest data as of 2026-07-13

AI commentary

Deterministic signals remain near-neutral, with low expected returns and only moderate thesis-change intensity, so this stays a monitoring-style Hold rather than a directional call. Primary evidence quality is strong because the April 28, 2026 earnings 8-K provides direct operating and guidance context, but forward visibility is still constrained by plant-execution risk. Headline buzz has been lifted by activist coverage, yet that should not be treated as core thesis support without company confirmation.

RankAlpha Sentiment Codex - 2026-07-13

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-07-31eventNext earnings update must validate the reset FY2026 outlookHigh impact

Management updated FY2026 sales guidance to $1.835-$1.870 billion and adjusted EBITDA guidance to $385-$400 million, mainly reflecting a slower-than-expected productivity ramp at Hopewell, so the next results checkpoint is the key test of stabilization versus the lower bar [#SEC-8K-2026-04-28].

2026-08-01catalystHopewell execution and Calvert normalization remain the clearest near-term swing factorsHigh impact

Ashland's April 28, 2026 earnings release said adjusted EBITDA fell year over year primarily because of the Calvert City startup delay, Hopewell productivity challenges, and weather disruptions, while also stating Calvert repairs were completed; evidence of a cleaner Hopewell ramp is still the most important near-term operating test [#SEC-8K-2026-04-28].

2026-12-31catalystResilient Life Sciences and Personal Care demand could support margin recovery if internal disruptions fadeHigh impact

Ashland highlighted resilient Life Sciences demand, continued pharma application volume growth, and broad-based Personal Care growth, while coatings returned to growth on share gains; if those businesses stay firm while manufacturing execution improves, recovery can extend beyond the immediate quarter [#SEC-8K-2026-04-28].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-07-13 • Updated nightlySource: Internal modelMethodology